AOD-9604 · DOSSIER

AOD-9604

Advanced Obesity Drug 9604 · hGH Fragment 176-191 · Peptide · 16 AS
LEGAL DE · NOT APPROVEDEVIDENCE · EARLY CLINICAL STUDIES2 STUDIESWADA · S2
FIG.01 — SIGNAL CHAIN
YLRIVQCRSVEGSCGF · ~1815.1 Da
02

Mechanism of action

What AOD-9604 does in the body — step by step.

01

AOD-9604 is a synthetic peptide fragment corresponding to the C-terminal region of human growth hormone (hGH, amino acids 177–191).

02

In preclinical studies, this fragment was described as mediating lipolytic (fat-degrading) effects in adipocytes without triggering the anabolic or growth-promoting effects of the full GH molecule.

03

A postulated mechanism of action involves interactions with beta-3 adrenergic receptors on fat cells.

03

Research status

How far along is the evidence?

PRECLINICALEARLY CLINICAL STUDIESCLINICALLY ESTABLISHED
AOD-9604 went through a full clinical development programme run by Metabolic Pharmaceuticals (Australia).
AOD-9604 went through a full clinical development programme run by Metabolic Pharmaceuticals (Australia).
Phase I studies showed favourable tolerability.
However, a Phase IIb study (n=536) over 24 weeks in obesity showed no significant difference from placebo in weight reduction.
The programme was discontinued.
In Australia, AOD-9604 was temporarily approved as a Novel Food ingredient (FSANZ); this status was later revoked.
As of February 2026, AOD-9604 was reclassified in the US by HHS/FDA into a category that again permits compounding pharmacies — which has driven increased interest on social media.
04

Known risks

Without human data, safety statements are limited. What is known:

01
Phase III efficacy in obesity failed — clinical benefit not established
02
Long-term safety data are lacking
03
Product quality and purity cannot be verified from unapproved sources
04
Possible interactions with other hormone systems not fully studied
05
Legal risk: WADA-listed; import may fall under the German Medicines Act (AMG)
05

Cited studies

Chronological — links lead to the source.

2001
Metabolic effects of growth hormone peptide analogues in obese adults
PubMed 11174349 →
2004
A placebo-controlled trial of the effect of hGH fragment (AOD9604) on adiposity and body composition in obese adults
PubMed 15272942 →
06

Frequently asked questions

What is AOD-9604?+

AOD-9604 is a synthetic peptide fragment corresponding to the C-terminal region of human growth hormone (hGH, amino acids 177–191).

What type of peptide is AOD-9604?+

AOD-9604 belongs to the Other class.

What is AOD-9604 used for?+

In research, AOD-9604 has primarily been investigated in the context of: Metabolism. These are research findings (evidence: early clinical studies), not proven benefits in humans and not a usage recommendation.

Is AOD-9604 legal in Germany?+

AOD-9604 is not approved as a medicine in Germany. Obtaining it outside clinical studies is legally problematic.

Is AOD-9604 FDA-approved / legal in the US?+

No. AOD-9604 is not FDA-approved as a drug in the US; it is mostly sold as a research chemical and not for human consumption.

Is AOD-9604 legal in Canada?+

No. AOD-9604 is not authorized by Health Canada and not intended for human consumption.

Where can I buy AOD-9604?+

Peptica sells nothing and names no sources. AOD-9604 is "not approved" in Germany; obtaining unapproved substances outside clinical studies is illegal and carries quality and safety risks.

What is the dosage of AOD-9604?+

Peptica publishes no dosing. There are no approved dosing guidelines for AOD-9604; figures circulating online stem from animal studies or anecdote, not from validated human protocols. This is not medical advice.

Is AOD-9604 banned in sport (WADA)?+

Yes. AOD-9604 is on the WADA Prohibited List and is therefore banned in competitive sport.

What are the known risks of AOD-9604?+

Documented risks include: Phase III efficacy in obesity failed — clinical benefit not established; Long-term safety data are lacking. This is not a complete safety assessment and not medical advice — see the risks section for the full list.

How well researched is AOD-9604?+

The evidence is classified as “early clinical studies”. 2 studies are cited on this page.

What is the molecular weight of AOD-9604?+

AOD-9604 has a molar mass of about 1815.1 Da.

Which peptides are related to AOD-9604?+

Closely related entries: Tesamorelin. A direct side-by-side comparison is available via the compare function.

07

Dossier

Legal · Structure · Sources.

LEGAL STATUS BY REGION
Germanynot approved

As a GH fragment, AOD-9604 is on the WADA Prohibited List (S2, section on GH-releasing factors and fragments). It is not approved as a medicine in the EU or Germany. The 2026 US FDA reclassification for compounding pharmacies has no effect on the German/European legal framework. Import and possession in Germany are legally problematic and may fall under the German Medicines Act (AMG).

Legal status varies by country and can change. This is not legal advice.

STRUCTURE & MOLECULE
H₂NYLRIVQCRSVEGSCGFCOOH
16
AMINO ACIDS
~1815.1
MOL. WEIGHT (Da)
Very short
HALF-LIFE
SOURCES & EXTERNAL DATABASES

Methodology: Peptica compiles publicly available studies and regulatory information and assigns each statement an evidence level. Not medical advice. No warranty.

RELATED PEPTIDES & FURTHER READING
08

Community notes

Note: These posts are user opinions and not medical advice. Posts containing dosages, therapeutic claims or purchase recommendations are removed. All entries are manually reviewed before publication.
This page is intended solely for factual, scientifically oriented information. No medical advice · no dosage or usage recommendations · no claims of efficacy · no substitute for medical consultation. Peptica sells no substances. Partner links are marked as advertising; Peptica may earn a commission. © 2026 Peptica · Issue 01